SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Clinical Trials
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Czaja, S. J
Right arrow Articles by Stahl, S. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Czaja, S. J
Right arrow Articles by Stahl, S. M
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Alzheimer's Caregivers
*Alzheimer's Disease
*Caregivers
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Data and safety monitoring in social behavioral intervention trials: the REACH II experience

Sara J Czaja

Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1695 N.W. 9th Ave., Suite 3204, Miami, Florida 33136, USA; sczaja{at}med.miami.edu

Richard Schulz

University Center for Social and Urban Research, University of Pittsburgh, Pittsburgh, PA, USA

Steven H Belle

Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

Louis D Burgio

Center for Mental Health & Aging, The University of Alabama, Tuscaloosa, AL, USA

Nell Armstrong

National Institute of Nursing Research/National Institutes of Health, Bethesda, MD, USA

Laura N Gitlin

Center for Applied Research on Aging and Health, Thomas Jefferson University, Philadelphia, PA, USA

David W Coon

Department of Social & Behavioral Sciences, Arizona State University, Glendale, AZ, USA

Jennifer Martindale-Adams

University of Tennessee-Memphis Health Science Center, VA Medical Center, Memphis, TN, USA

Julie Klinger

University Center for Social and Urban Research, University of Pittsburgh, Pittsburgh, PA, USA

Sidney M Stahl

Behavioral and Social Research Program, National Institute on Aging/National Institutes of Health, Bethesda, MD, USA

Background Psychosocial and behavioral interventions trials targeting a broad range of complex social and behavioral problems such as smoking, obesity and family caregiving have proliferated in the past 30 years. At the same time the use of Data and Safety Monitoring Boards (DSMBs) to monitor the progress and quality of intervention trials and the safety of study participants has increased substantially. Most of the existing literature and guidelines for safety monitoring and reporting of adverse events focuses on medical interventions. Consequently, there is little guidance for investigators conducting social and behavior trials.

Purpose This paper summarizes how issues associated with safety monitoring and adverse event reporting were handled in the Resources for Enhancing Alzheimer's Caregiver Health (REACH II) program, a multi-site randomized clinical trial, funded by the National Institutes on Aging (NIA) and the National Institutes of Nursing Research (NINR), that tested the efficacy of a multicomponent social/behavioral intervention for caregivers of persons with Alzheimer's disease.

Methods A task force was formed to define adverse events for the trial and protocols for reporting and resolving events that occurred. The task force conducted a review of existing polices and protocols for data and safety monitoring and adverse event reporting and identified potential risks particular to the study population. An informal survey regarding data and safety monitoring procedures with investigators on psychosocial intervention trials was also conducted.

Results Two categories of events were defined for both caregivers and patients; adverse events and safety alerts. A distinction was also made between events detected at baseline assessment and those detected post-randomization. Standardized protocols were also developed for the reporting and resolution of events that occurred and training of study personnel. Results from the informal survey indicated wide variability in practices for data safety and monitoring across psychosocial intervention trials.

Conclusions Overall, the REACH II experience demonstrates that existing guidelines regarding safety monitoring and adverse event reporting pose unique challenges for social/behavioral intervention trials. Challenges encountered in the REACH II program included defining and classifying adverse events, defining "resolution" of adverse events and attributing causes for events that occurred. These challenges are highlighted and recommendations for addressing them in future studies are discussed.

Clinical Trials, Vol. 3, No. 2, 107-118 (2006)
DOI: 10.1191/1740774506cn136oa


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement